As of January 18, 2023, Portugal had the highest COVID-19 vaccination rate in Europe having administered 272.78 doses per 100 people in the country, while Malta had administered 258.49 doses per 100. The UK was the first country in Europe to approve the Pfizer/BioNTech vaccine for widespread use and began inoculations on December 8, 2020, and so far have administered 224.04 doses per 100. At the latest data, Belgium had carried out 253.89 doses of vaccines per 100 population. Russia became the first country in the world to authorize a vaccine - named Sputnik V - for use in the fight against COVID-19 in August 2020. As of August 4, 2022, Russia had administered 127.3 doses per 100 people in the country.

The seven-day rate of cases across Europe shows an ongoing perspective of which countries are worst affected by the virus relative to their population. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

As of March 20, 2023, around 391 doses of COVID-19 vaccines per 100 people in Cuba had been administered, one of the highest COVID-19 vaccine dose rates of any country worldwide. This statistic shows the rate of COVID-19 vaccine doses administered worldwide as of March 20, 2023, by country or territory.

By August 2024, Cuba had administered the largest number of vaccines against COVID-19 per 100 inhabitants in the Latin American region, followed by Chile and Peru. According to recent estimates, the Caribbean country applied around 410 doses per 100 population, accounting for one of the largest vaccination rates observed not only in the Latin American region, but worldwide. In comparison, Haiti registered the lowest vaccination rate within the region, with only 5.87 doses administered per 100 inhabitants. Booster shots started To reinforce the immune protection against the fast spread of the SARS-CoV-2, governments began to introduce booster shots in their immunization programs aiming at strengthening people’s immune response against new contagious COVID-19 variants. In Latin America, Cuba was leading on booster shots relative to its population among a selection of countries, with around 88 percent of the population receiving the extra dose. In comparison, these numbers are higher than those for the European Union and the United States. Pharmaceutical research continues As Omicron becomes more prominent worldwide, and recombinant variants emerge, research efforts to prevent and control the disease continue to progress. As of June 2022, there were around 2,700 clinical trials to treat COVID-19 and 1,752 COVID-19 vaccines trials in clinical development. Other studies were focused on mild, moderate and severe COVID-19, complication support, and post-COVID symptoms, among others.For further information about the coronavirus (COVID-19) pandemic, please visit our dedicated Facts and Figures page.

As of January 17, 2023, 96.3 percent of adults in Ireland had been fully vaccinated against COVID-19. According to the manufacturers of the majority of COVID-19 vaccines currently in use in Europe, being fully vaccinated is when a person receives two doses of the vaccine. In Portugal, 94.2 percent of adults had received a full course of the COVID-19 vaccination, as well as 93.9 percent of those in Malta had been fully vaccinated. On the other hand, only 35.8 percent of adults in Bulgaria had been fully vaccinated.

Furthermore, the seven-day rate of cases across Europe shows which countries are currently worst affected by the situation. For further information about the coronavirus pandemic, please visit our dedicated Facts and Figures page.

About this Dataset

The data contains the following information:

Country- this is the country for which the vaccination information is provided; Country ISO Code - ISO code for the country; Date - date for the data entry; for some of the dates we have only the daily vaccinations, for others, only the (cumulative) total; Total number of vaccinations - this is the absolute number of total immunizations in the country; Total number of people vaccinated - a person, depending on the immunization scheme, will receive one or more (typically 2) vaccines; at a certain moment, the number of vaccination might be larger than the number of people; Total number of people fully vaccinated - this is the number of people that received the entire set of immunization according to the immunization scheme (typically 2); at a certain moment in time, there might be a certain number of people that received one vaccine and another number (smaller) of people that received all vaccines in the scheme; Daily vaccinations (raw) - for a certain data entry, the number of vaccination for that date/country; Daily vaccinations - for a certain data entry, the number of vaccination for that date/country; Total vaccinations per hundred - ratio (in percent) between vaccination number and total population up to the date in the country; Total number of people vaccinated per hundred - ratio (in percent) between population immunized and total population up to the date in the country; Total number of people fully vaccinated per hundred - ratio (in percent) between population fully immunized and total population up to the date in the country; Number of vaccinations per day - number of daily vaccination for that day and country; Daily vaccinations per million - ratio (in ppm) between vaccination number and total population for the current date in the country; Vaccines used in the country - total number of vaccines used in the country (up to date); Source name - source of the information (national authority, international organization, local organization etc.); Source website - website of the source of information;

Tasks: Track the progress of COVID-19 vaccination What vaccines are used and in which countries? What country is vaccinated more people? What country is vaccinated a larger percent from its population?

This data is valuble in relation to the health, financial, and engineering sectors.

Category

Health & Medicine

Keywords

Health,Medicine,covid-19,dataset,progress

Row Count

5824

Price

$120.00

This study provides a macro-level societal and health system focused analysis of child vaccination rates in 30 European countries, exploring the effect of context on coverage. The importance of demography and health system attributes on health care delivery are recognized in other fields, but generally overlooked in vaccination. The analysis is based on correlating systematic data built up by the Models of Child Health Appraised (MOCHA) Project with data from international sources, so as to exploit a one-off opportunity to set the analysis within an overall integrated study of primary care services for children, and the learning opportunities of the ‘natural European laboratory’. The descriptive analysis shows an overall persistent variation of coverage across vaccines with no specific vaccination having a low rate in all the EU and EEA countries. However, contrasting with this, variation between total uptake per vaccine across Europe suggests that the challenge of low rates is related to country contexts of either policy, delivery, or public perceptions. Econometric analysis aiming to explore whether some population, policy and/or health system characteristics may influence vaccination uptake provides important results - GDP per capita and the level of the population’s higher education engagement are positively linked with higher vaccination coverage, whereas mandatory vaccination policy is related to lower uptake rates. The health system characteristics that have a significant positive effect are a cohesive management structure; a high nurse/doctor ratio; and use of practical care delivery reinforcements such as the home-based record and the presence of child components of e‑health strategies.

Context

Country-Level Information On COVID-19 Cases

Content

Dataset : COVID-19 Dataset.csv

It Contains: Continent Name Country Name Last Updated Date Total Cases Total Deaths Total Cases Per Million Total Deaths Per Million Total Tests Positivity Rate Total Vaccinations People Vaccinated People Fully Vaccinated Population Density of the Country Median Age Aged 65 Older Aged 70 Older GDP Per Capita of the Country

Acknowledgements

• ourworldindata.org : ourworldindata.org/coronavirus-source-data
• World Health Organization (WHO): https://www.who.int/

Global Veterinary Vaccines Except for Foot and Mouth Market Size Value Per Capita by Country, 2023 Discover more data with ReportLinker!

As of April 25, 2022, Mauritius was the African country with the highest number of coronavirus (COVID-19) doses secured per capita. The country had received 3.12 COVID-19 vaccine doses per capita through bilateral agreements, donations, and the COVAX initiative. Seychelles and Rwanda followed with 2.33 and 2.24 doses per capita, respectively.

Context

The data is collected from OWID (Our World in Data) GitHub repository, which is updated on daily bases.

Content

This dataset contains only one file vaccinations.csv, which contains the records of vaccination doses received by people from all the countries. * location: name of the country (or region within a country). * iso_code: ISO 3166-1 alpha-3 – three-letter country codes. * date: date of the observation. * total_vaccinations: total number of doses administered. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses). If a person receives one dose of the vaccine, this metric goes up by 1. If they receive a second dose, it goes up by 1 again. * total_vaccinations_per_hundred: total_vaccinations per 100 people in the total population of the country. * daily_vaccinations_raw: daily change in the total number of doses administered. It is only calculated for consecutive days. This is a raw measure provided for data checks and transparency, but we strongly recommend that any analysis on daily vaccination rates be conducted using daily_vaccinations instead. * daily_vaccinations: new doses administered per day (7-day smoothed). For countries that don't report data on a daily basis, we assume that doses changed equally on a daily basis over any periods in which no data was reported. This produces a complete series of daily figures, which is then averaged over a rolling 7-day window. An example of how we perform this calculation can be found here. * daily_vaccinations_per_million: daily_vaccinations per 1,000,000 people in the total population of the country. * people_vaccinated: total number of people who received at least one vaccine dose. If a person receives the first dose of a 2-dose vaccine, this metric goes up by 1. If they receive the second dose, the metric stays the same. * people_vaccinated_per_hundred: people_vaccinated per 100 people in the total population of the country. * people_fully_vaccinated: total number of people who received all doses prescribed by the vaccination protocol. If a person receives the first dose of a 2-dose vaccine, this metric stays the same. If they receive the second dose, the metric goes up by 1. * people_fully_vaccinated_per_hundred: people_fully_vaccinated per 100 people in the total population of the country.

Note: for people_vaccinated and people_fully_vaccinated we are dependent on the necessary data being made available, so we may not be able to make these metrics available for some countries.

Acknowledgements

This data collected by Our World in Data which gets updated daily on their Github.

Inspiration

Possible uses for this dataset could include: - Sentiment analysis in a variety of forms - Statistical analysis over time.

Context

To be honest it's pretty hard for you to find data on vaccine progress and especially time-based data on a country like Pakistan. So, I created this small but interactive notebook that will keep updating the database until everyone is vaccinated. In this project I have used Pandas for easy WebSracping to get the data from pharmaceutical-technology.com then I have created Sqlite3 database to store the data into three tables. It took me a few tries to get everything working smooth so I started using SQL queries to get the data and then used plotly to plot interactive visualization. I was not sure when they will update the website so, I have created few functions to avoid duplication of data and to inform me on telegram about updates. I have also uploaded the processed data to Kaggle from Deepnote which will be updated daily. At last, I have used the Deepnote Schedule notebook feature to run this notebook every day and successfully publishing the article You can find my work on Deepnote.

Content

• World_Vaccination_Progress.csv -> Countries Vaccination progress
• pakistan_time_series.csv -> Time series data of Pakistan vaccine progress
• world_time_series.csv -> Time series data of World vaccine progress

Columns: - Country :: Names of countries in the world - Doses Administered: Total Doses Administered - Doses per 1000 : Number of Doses per thousand - Fully Vaccinated Population (%) : Percentage of a fully vaccinated person in a country. - Vaccine being used in a country : Types of vaccines used in a country.

For Time-Series

• Date_Time : Timestamp of entry

Acknowledgements

I am thankful for Pharmaceutical Technology for updating the stats on daily basis and publicly provide real-time stats of world's vaccination drive. I also want to thank Deepnote for the introduction of the Schedule notebook feature that has made this automation possible.

Inspiration

The lack of data available in my country drove me to create an automated system that collects data from web. You can read more about it in my article. The second inspiration came from participating in Deepnote competition which was on the data Vaccination drive of your country or World.

Context

Covid-19 Data collected from various sources on the internet. This dataset has daily level information on the number of affected cases, deaths, and recovery from the 2019 novel coronavirus. Please note that this is time-series data and so the number of cases on any given day is the cumulative number.

Content

The dataset includes 28 files scrapped from various data sources mainly the John Hopkins GitHub repository, the ministry of health affairs India, worldometer, and Our World in Data website. The details of the files are as follows

• countries-aggregated.csv A simple and cleaned data with 5 columns with self-explanatory names. -covid-19-daily-tests-vs-daily-new-confirmed-cases-per-million.csv A time-series data of daily test conducted v/s daily new confirmed case per million. Entity column represents Country name while code represents ISO code of the country. -covid-contact-tracing.csv Data depicting government policies adopted in case of contact tracing. 0 -> No tracing, 1-> limited tracing, 2-> Comprehensive tracing. -covid-stringency-index.csv The nine metrics used to calculate the Stringency Index are school closures; workplace closures; cancellation of public events; restrictions on public gatherings; closures of public transport; stay-at-home requirements; public information campaigns; restrictions on internal movements; and international travel controls. The index on any given day is calculated as the mean score of the nine metrics, each taking a value between 0 and 100. A higher score indicates a stricter response (i.e. 100 = strictest response). -covid-vaccination-doses-per-capita.csv A total number of vaccination doses administered per 100 people in the total population. This is counted as a single dose, and may not equal the total number of people vaccinated, depending on the specific dose regime (e.g. people receive multiple doses). -covid-vaccine-willingness-and-people-vaccinated-by-country.csv Survey who have not received a COVID vaccine and who are willing vs. unwilling vs. uncertain if they would get a vaccine this week if it was available to them. -covid_india.csv India specific data containing the total number of active cases, recovered and deaths statewide. -cumulative-deaths-and-cases-covid-19.csv A cumulative data containing death and daily confirmed cases in the world. -current-covid-patients-hospital.csv Time series data containing a count of covid patients hospitalized in a country -daily-tests-per-thousand-people-smoothed-7-day.csv Daily test conducted per 1000 people in a running week average. -face-covering-policies-covid.csv Countries are grouped into five categories: 1->No policy 2->Recommended 3->Required in some specified shared/public spaces outside the home with other people present, or some situations when social distancing not possible 4->Required in all shared/public spaces outside the home with other people present or all situations when social distancing not possible 5->Required outside the home at all times regardless of location or presence of other people -full-list-cumulative-total-tests-per-thousand-map.csv Full list of total tests conducted per 1000 people. -income-support-covid.csv Income support captures if the government is covering the salaries or providing direct cash payments, universal basic income, or similar, of people who lose their jobs or cannot work. 0->No income support, 1->covers less than 50% of lost salary, 2-> covers more than 50% of the lost salary. -internal-movement-covid.csv Showing government policies in restricting internal movements. Ranges from 0 to 2 where 2 represents the strictest. -international-travel-covid.csv Showing government policies in restricting international movements. Ranges from 0 to 2 where 2 represents the strictest. -people-fully-vaccinated-covid.csv Contains the count of fully vaccinated people in different countries. -people-vaccinated-covid.csv Contains the total count of vaccinated people in different countries. -positive-rate-daily-smoothed.csv Contains the positivity rate of various countries in a week running average. -public-gathering-rules-covid.csv Restrictions are given based on the size of public gatherings as follows: 0->No restrictions 1 ->Restrictions on very large gatherings (the limit is above 1000 people) 2 -> gatherings between 100-1000 people 3 -> gatherings between 10-100 people 4 -> gatherings of less than 10 people -school-closures-covid.csv School closure during Covid. -share-people-fully-vaccinated-covid.csv Share of people that are fully vaccinated. -stay-at-home-covid.csv Countries are grouped into four categories: 0->No measures 1->Recommended not to leave the house 2->Required to not leave the house with exceptions for daily exercise, grocery shopping, and ‘essent...

ImportanceGovernments have introduced non-pharmaceutical interventions (NPIs) in response to the pandemic outbreak of Coronavirus disease (COVID-19). While NPIs aim at preventing fatalities related to COVID-19, the previous literature on their efficacy has focused on infections and on data of the first half of 2020. Still, findings of early NPI studies may be subject to underreporting and missing timeliness of reporting of cases. Moreover, the low variation in treatment timing during the first wave makes identification of robust treatment effects difficult.ObjectiveWe enhance the literature on the effectiveness of NPIs with respect to the period, the number of countries, and the analytical approach.Design, Setting, and ParticipantsTo circumvent problems of reporting and treatment variation, we analyse data on daily confirmed COVID-19-related deaths per capita from Our World in Data, and on 10 different NPIs from the Oxford COVID-19 Government Response Tracker (OxCGRT) for 169 countries from 1st July 2020 to 1st September 2021. To identify the causal effects of introducing NPIs on COVID-19-related fatalities, we apply the generalized synthetic control (GSC) method to each NPI, while controlling for the remaining NPIs, weather conditions, vaccinations, and NPI-residualized COVID-19 cases. This mitigates the influence of selection into treatment and allows to model flexible post-treatment trajectories.ResultsWe do not find substantial and consistent COVID-19-related fatality-reducing effects of any NPI under investigation. We see a tentative change in the trend of COVID-19-related deaths around 30 days after strict stay-at-home rules and to a slighter extent after workplace closings have been implemented. As a proof of concept, our model is able to identify a fatality-reducing effect of COVID-19 vaccinations. Furthermore, our results are robust with respect to various crucial sensitivity checks.ConclusionOur results demonstrate that many implemented NPIs may not have exerted a significant COVID-19-related fatality-reducing effect. However, NPIs might have contributed to mitigate COVID-19-related fatalities by preventing exponential growth in deaths. Moreover, vaccinations were effective in reducing COVID-19-related deaths.

The global pediatric preventable vaccine market, valued at approximately $30.78 billion in 2025, is poised for substantial growth over the forecast period (2025-2033). While the precise Compound Annual Growth Rate (CAGR) is unavailable, considering the increasing global immunization initiatives, rising prevalence of vaccine-preventable diseases, and the continuous development of new and improved vaccines (mRNA and viral vector vaccines, for example), a conservative estimate of a 5-7% CAGR is reasonable. This growth is driven by factors such as increased government funding for vaccination programs, rising awareness among parents regarding the importance of childhood immunizations, and the expanding reach of healthcare infrastructure, particularly in developing nations. The market segmentation reveals strong demand across various vaccine types, including live, inactivated, subunit, mRNA, and viral vector vaccines, with live vaccines potentially holding the largest share due to their effectiveness and widespread use. Key application areas include bacterial and viral diseases, reflecting the broad scope of preventable illnesses targeted by pediatric vaccines. Geographic distribution shows strong market presence in North America and Europe, driven by high per capita income and developed healthcare systems. However, significant growth opportunities exist in emerging economies of Asia-Pacific and Africa, where expanding immunization coverage presents considerable potential for market expansion. Increased investment in research and development of innovative vaccine technologies will further propel market growth. The market faces certain restraints, primarily related to vaccine hesitancy and concerns about adverse effects. However, robust public health campaigns aiming to address these concerns and the continuous improvement in vaccine safety profiles are mitigating these challenges. Competition among major pharmaceutical companies such as Pfizer, Merck, GSK, Sanofi Pasteur, and Moderna is intense, driving innovation and price competition. The market landscape also includes significant players from emerging markets, such as Serum Institute of India and Bharat Biotech, which are expanding their global reach and contributing to increased vaccine accessibility. The ongoing evolution of vaccine technologies, including the development of combination vaccines and novel delivery systems, will likely shape the market's future trajectory, further increasing efficiency and cost-effectiveness.

• GDP  =  gross domestic product; I$  =  international dollars. Values represent the added cost of the 9-valent HPV vaccine at which the incremental cost-effectiveness ratio (compared to current 2- or 4-valent vaccines) would be equal to 1x per capita GDP in each country.† Base case scenario  =  some benefits to prevent cervical cancer with unidentifiable types and multiple infections, defined as a function of the prevalence of the five targeted HPV types relative to the prevalence of all non-16/18 types, with 37.4% cross-protection against non-vaccine types.Impact of discount rate on thresholds of incremental cost (I$) per vaccinated girl associated with the 9-valent vaccine*.

• GDP  =  gross domestic product; I$  =  international dollars. Values represent the added cost of the 9-valent HPV vaccine at which the incremental cost-effectiveness ratio (compared to current 2- or 4-valent vaccines) would be equal to 1x or 3x per capita GDP in each country.† Base case scenario  =  some benefits to prevent cervical cancer with unidentifiable types and multiple infections, defined as a function of the prevalence of the five targeted HPV types relative to the prevalence of all non-16/18 types, with 37.4% cross-protection against non-vaccine types.Thresholds of incremental cost (I$) per vaccinated girl associated with the 9-valent vaccine in Kenya and Uganda (discounting rate  = 3% per year)*.

The global animal health vaccination market is experiencing robust growth, driven by increasing pet ownership, rising awareness of zoonotic diseases, and the expanding livestock industry. The market, estimated at $15 billion in 2025, is projected to witness a Compound Annual Growth Rate (CAGR) of 7% from 2025 to 2033, reaching approximately $25 billion by 2033. This growth is fueled by several key factors. Firstly, the increasing prevalence of infectious diseases in both livestock and companion animals necessitates proactive vaccination strategies to prevent outbreaks and reduce economic losses. Secondly, technological advancements in vaccine development, such as the emergence of more effective and safer DNA vaccines, are driving market expansion. Thirdly, stringent government regulations promoting animal welfare and disease control are creating a favorable regulatory environment. Finally, the growing demand for high-quality animal protein sources globally is also contributing to increased vaccination rates in the livestock sector. Market segmentation reveals that livestock vaccinations currently hold the largest market share, driven by large-scale farming operations and the need for herd immunity. However, the pet vaccination segment is exhibiting rapid growth, reflecting the increasing humanization of pets and rising veterinary care expenditure. Within vaccine types, live attenuated vaccines dominate due to their efficacy, but inactivated and DNA vaccines are gaining traction owing to improved safety profiles and enhanced targeted delivery mechanisms. Geographically, North America and Europe currently hold significant market shares due to established veterinary infrastructure and high per capita animal healthcare spending. However, rapidly developing economies in Asia-Pacific are emerging as lucrative markets, driven by increasing livestock production and rising pet ownership. Major players like Merck, Zoetis, and Boehringer Ingelheim are dominating the market through robust R&D, extensive distribution networks, and strategic acquisitions. However, emerging regional companies are also gaining ground, particularly in Asia, presenting a competitive landscape.

The global market for Recombinant Novel Coronavirus Vaccine for Inhalation is experiencing robust growth, driven by the increasing demand for convenient and effective vaccination methods. While precise figures for market size in 2025 are unavailable, considering the significant investment in respiratory vaccine development post-pandemic and the inherent advantages of inhaled delivery (e.g., ease of administration, potential for broader mucosal immunity), we can reasonably estimate the market size to be around $500 million in 2025. This estimate is supported by the substantial investments being made in this area by key players like CanSino Bio and Aerogen, coupled with the ongoing research and development efforts globally. We project a Compound Annual Growth Rate (CAGR) of 15% from 2025 to 2033, fueled by factors such as growing awareness of respiratory infections, technological advancements in vaccine delivery systems, and the potential for broader application beyond COVID-19 to other respiratory viruses. This translates to a significant market expansion, reaching an estimated value exceeding $2 billion by 2033. Several factors contribute to this growth trajectory. The ongoing need for effective vaccination strategies against emerging respiratory viruses, combined with the convenience and potential efficacy improvements offered by inhaled vaccines, represent key drivers. However, challenges such as regulatory hurdles, manufacturing complexities, and the need for large-scale clinical trials to confirm efficacy and safety profiles across different populations represent potential restraints. Market segmentation reveals strong demand across hospital and outpatient settings, with the 'others' segment likely to grow significantly as the technology matures and finds applications in other vaccination campaigns. The geographic distribution shows a high concentration of initial market penetration in North America and Europe, due to advanced healthcare infrastructure and higher per capita income, while the Asia-Pacific region exhibits significant growth potential in the long term given its large population base.

The global vaccine glass bottle market is experiencing steady growth, driven by the increasing demand for vaccines globally. The market, valued at approximately $2.5 billion in 2025, is projected to exhibit a compound annual growth rate (CAGR) of 5% from 2025 to 2033. This growth is fueled by several factors, including rising vaccination rates worldwide, the ongoing development of new vaccines for emerging infectious diseases, and a growing preference for single-dose vials to minimize wastage and enhance safety. The increasing prevalence of chronic diseases requiring therapeutic vaccines further contributes to market expansion. Market segmentation reveals that the multi-dose segment currently holds a larger market share than the single-dose segment due to cost-effectiveness for mass vaccination programs. However, the single-dose segment is expected to witness faster growth driven by its advantages in preventing contamination and ensuring individual dosage accuracy. Within applications, preventive vaccines dominate the market share, mirroring the global focus on preventing infectious diseases. However, the therapeutic vaccine segment is expected to grow at a faster rate due to increased investment in the development of vaccines for treating chronic diseases like cancer. Key players such as Schott, Thermo Fisher Scientific, and Gerresheimer are leveraging their technological expertise to cater to the growing demands of the pharmaceutical industry, further fueling market expansion. Geographical analysis indicates that North America and Europe currently hold significant market shares, driven by robust healthcare infrastructure and high per capita vaccine consumption. However, Asia Pacific is projected to emerge as a high-growth region in the coming years due to rising disposable incomes, increasing healthcare expenditure, and expanding vaccination programs, particularly in countries like India and China. The market faces challenges such as stringent regulatory requirements for pharmaceutical packaging, intense competition among manufacturers, and potential fluctuations in raw material prices. Despite these challenges, the long-term outlook for the vaccine glass bottle market remains positive, driven by continuous innovation in vaccine technology and the global commitment to improving public health.

Vaccination is considered as the main tool for the Global Control and Eradication Strategy for peste des petits ruminants (PPR), and the efficacity of the PPR-vaccine in conferring long-life immunity has been established. Despite this, previous studies asserted that vaccination can be expensive and consequently, the effectiveness of disease control may not necessarily translate to overall profit for farmers. Also, the consequences of PPR control on socioeconomic indicators like food and nutrition security at a macro-national level have not been explored thoroughly. Therefore, this study seeks to assess ex-ante the impact of PPR control strategies on farm-level profitability and the socioeconomic consequences concerning food and nutrition security at a national level in Senegal. A bi-level system dynamics model, compartmentalised into five modules consisting of integrated production-epidemiological, economics, disease control, marketing, and policy modules, was developed with the STELLA Architect software, validated, and simulated for 30 years at a weekly timestep. The model was parameterised with data from household surveys from pastoral areas in Northern Senegal and relevant existing data. Nine vaccination scenarios were examined considering different vaccination parameters (vaccination coverage, vaccine wastage, and the provision of government subsidies). The findings indicate that compared to a no-vaccination scenario, all the vaccination scenarios for both 26.5% (actual vaccination coverage) and 70% (expected vaccination coverage) resulted in statistically significant differences in the gross margin earnings and the potential per capita consumption for the supply of mutton and goat meat. At the prevailing vaccination coverage (with or without the provision of government subsidies), farm households will earn an average gross margin of $69.43 (annually) more than without vaccination, and the average per capita consumption for mutton and goat meat will increase by 1.13kg/person/year. When the vaccination coverage is increased to the prescribed threshold for PPR eradication (i.e., 70%), with or without the provision of government subsidies, the average gross margin earnings would be $72.23 annually and the per capita consumption will increase by 1.23kg/person/year compared to the baseline (without vaccination). This study’s findings offer an empirical justification for a sustainable approach to PPR eradication. The information on the socioeconomic benefits of vaccination can be promoted via sensitization campaigns to stimulate farmers’ uptake of the practice. This study can inform investment in PPR control.